These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 11809)

  • 21. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
    Cox B; Kastin AJ; Schnieden H
    Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenergic nonspecific potentiation of yohimbine toxicity in mice by antidepressants and related drugs and antiyohimbine action of antiadrenergic and serotonergic drugs.
    Lapin IP
    Psychopharmacology (Berl); 1980; 70(2):179-85. PubMed ID: 6776578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs.
    Steru L; Chermat R; Thierry B; Mico JA; Lenegre A; Steru M; Simon P; Porsolt RD
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(6):659-71. PubMed ID: 2894041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the DOPA-potentiation test.
    Spirtes MA; Plotnikoff NP; Kostrzewa RM; Harston CT; Kastin AJ; Christensen CW
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):121-4. PubMed ID: 13411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THE EFFECT OF PSYCHOTROPIC DRUGS ON THE METABOLISM OF EXOGENOUS DL-2-C14-3,4-DIHYDROXYPHENYLALANINE.
    PLETSCHER A; GEY KF
    Med Exp Int J Exp Med; 1964; 11():169-76. PubMed ID: 14193975
    [No Abstract]   [Full Text] [Related]  

  • 28. Neuroleptics as a guideline to biological research in psychotic disorders.
    van Praag HM
    Compr Psychiatry; 1975; 16(1):7-22. PubMed ID: 1089049
    [No Abstract]   [Full Text] [Related]  

  • 29. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Action of some centrally active drugs and heavy metals on in vitro oxidation of dopamine by rat brain tissue.
    Bhatnagar SP
    Can J Physiol Pharmacol; 1972 Nov; 50(11):1080-5. PubMed ID: 4640801
    [No Abstract]   [Full Text] [Related]  

  • 31. Caesium ion: antagonism to chlorpromazine- and L-dopa- produced behavioural depression in mice.
    Messina FS
    J Pharm Pharmacol; 1975 Nov; 27(11):873-4. PubMed ID: 1502
    [No Abstract]   [Full Text] [Related]  

  • 32. Melanocyte-stimulating hormone release-inhibiting factor (MIF): lack of dopaminergic and anticholinergic activity.
    Carolei A; Margotta V; Palladini G
    Neuroendocrinology; 1977; 23(3):129-32. PubMed ID: 19714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel analogs of tricyclic psychopharmacological agents.
    Eichstadt KE; Reepmeyer JC; Cook RB; Riley PG; Davis DP; Wiley RA
    J Med Chem; 1976 Jan; 19(1):47-51. PubMed ID: 1246052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human pharmacology of antipsychotic and antidepressant drugs.
    Hollister LE
    Annu Rev Pharmacol; 1968; 8():491-516. PubMed ID: 4875400
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of protease inhibitors on the antidepressant activity of oxytocin.
    Arletti R; Bertolini A
    Neuropeptides; 1987 Oct; 10(3):241-8. PubMed ID: 2891075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological studies on drug interaction. V. Effect of adenyl compounds on L-dopa (author's transl)].
    Ozawa H; Ikeda M; Shoji T
    Yakugaku Zasshi; 1977 Oct; 97(10):1101-6. PubMed ID: 592101
    [No Abstract]   [Full Text] [Related]  

  • 37. POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT DRUGS BY TRYPTOPHAN.
    Wålinder J; Carlsson A; Persson R; Wallin L
    Acta Psychiatr Scand; 1980 Mar; 61(S280):242-249. PubMed ID: 28678370
    [No Abstract]   [Full Text] [Related]  

  • 38. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Oct; 16(4):273-301. PubMed ID: 359311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The action of psychotropic drugs on DOPA induced behavioural responses in mice.
    Berendsen H; Leonard BE; Rigter H
    Arzneimittelforschung; 1976; 26(9):1686-9. PubMed ID: 11809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.